Meridian Bioscience (VIVO) Receives Media Sentiment Score of 0.03
Headlines about Meridian Bioscience (NASDAQ:VIVO) have trended somewhat positive recently, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Meridian Bioscience earned a news sentiment score of 0.03 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.5754573888847 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Meridian Bioscience (NASDAQ:VIVO) opened at $15.00 on Tuesday. The company has a current ratio of 5.85, a quick ratio of 4.04 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $643.08, a P/E ratio of 29.41 and a beta of 0.98. Meridian Bioscience has a 52-week low of $12.30 and a 52-week high of $16.45.
Meridian Bioscience (NASDAQ:VIVO) last posted its earnings results on Thursday, January 25th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. The firm had revenue of $52.30 million during the quarter, compared to the consensus estimate of $49.00 million. Meridian Bioscience had a return on equity of 17.09% and a net margin of 10.46%. The company’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.15 EPS. sell-side analysts predict that Meridian Bioscience will post 0.69 earnings per share for the current fiscal year.
A number of research analysts have recently commented on the company. BidaskClub downgraded Meridian Bioscience from a “hold” rating to a “sell” rating in a research report on Saturday. Canaccord Genuity increased their target price on Meridian Bioscience from $14.00 to $16.00 and gave the company a “hold” rating in a research report on Friday, January 26th. Finally, Zacks Investment Research downgraded Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Sunday, January 21st.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.